Market Research Logo

Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market

Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market

Summary


Uveitis refers to inflammation of the uvea, the middle vascular coat of the eye, comprising the iris, ciliary body, and choroid. It may also involve other adjacent tissues of the eye. Uveitis occurs at any age, but it most commonly affects individuals between 20 and 59 years of age. However, this trend is changing; the percentage of elderly uveitis patients has been increasing in recent years. Uveitis represents a major cause of ocular morbidity worldwide and often results in complications such as cataracts, glaucoma, ocular hypertension, macular issues, and retinal detachment.

It is a leading cause of blindness in both developed and developing countries and is the fifth most common cause of vision loss in the developed world. The uveitis market is characterized by a small selection of marketed drug options, consisting of corticosteroid therapies, immunosuppressive therapies and biologics. Historically, corticosteroid therapies have made up the bulk of the uveitis market.

Currently only one targeted therapy is available in the Asia-Pacific uveitis market, which is AbbVie’s Humira (adalimumab). The late-stage uveitis pipeline is composed of Santen’s Opsiria and Clearside Biomedical’s CLS-TA, which are expected to be highly lucrative and address some of the unmet needs.

These new drugs will expand the options available to treat uveitis patients and contribute to overall market growth by offering novel treatment mechanisms, including new drug delivery routes and novel, non-corticosteroid drug molecules.

Scope

  • The Asia-Pacific uveitis market will be valued at $405.5m in 2023, growing from $179m in 2016, at a compound annual growth rate of 12.4%.
  • What are the key factors driving the Asia-Pacific uveitis treatment market?
  • How will targeted therapies such as Humira contribute to growth?
  • Do branded therapies show continuous growth, and are they facing competition from generics?
  • How will branded therapies be affected by upcoming pipeline therapies?
  • Corticosteroid therapies dominate the uveitis market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs?
  • What are the common targets and mechanisms of action of pipeline therapies?
  • What are the commercial prospects for the most promising late-stage products?
  • Various drivers and barriers will influence the market over the forecast period.
  • What are the barriers that will limit the uptake of premium-priced therapies in the assessed countries?
  • Which factors are most likely to drive the market in these countries?
  • What licensing and co-development deals have occurred within this therapy area since 2006?
Reasons to buy
  • Understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, epidemiology, prognosis and treatment.
  • Visualize the composition of the uveitis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
  • Analyze the uveitis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
  • Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
  • Predict uveitis market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
  • Identify commercial opportunities in the uveitis deals landscape by analyzing trends in licensing and co-development deals.


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Disease Introduction
      • Table Uveitis Therapeutics Market, APAC, Anatomic Classification of Uveitis
      • Table Uveitis Therapeutics Market, APAC, Definition of Onset, Duration and Course of Uveitis
    • Epidemiology
    • Symptoms
    • Etiology and Pathophysiology
      • Autoimmune uveitis
      • Non-autoimmune uveitis
        • Table Uveitis Therapeutics, APAC, Diseases Most Frequently Associated with Uveitis
    • Diagnosis
      • Table Uveitis Therapeutics, APAC, Investigations for Systemic Conditions Causing Uveitis
    • Prognosis
      • Table Uveitis Therapeutics Market, APAC, Prognosis for Uveitis Patients
    • Treatment Options
      • Corticosteroids
      • Immunosuppressive Agents
      • Biologics
      • Adjuvant Therapy
  • Marketed Products
    • Overview
      • Humira (adalimumab) –AbbVie
      • Retisert (fluocinolone acetonide) –Bausch & Lomb
      • Ozurdex (dexamethasone) –Allergan
      • Neoral (Cyclosporine) –Novartis
      • Mycept (Mycophenolate mofetil) –Panacea Biotec
      • Medrol (Methylprednisolone) –Pfizer
      • Betamethasone – Merck & Co.
      • Pred Forte (Prednisolone) –Allergan
    • Comparative Efficacy and Safety of Marketed Products
      • Table Figure 1: Uveitis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Uveitis
  • Pipeline Analysis
    • Overview
    • Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
      • Table Figure 2: Uveitis Therapeutics Market, Global, Pipeline, 2017
    • Pipeline by Molecular Target
      • Table Figure 3: Uveitis Therapeutics Market, Global, Pipeline by Molecular Target, 2017
    • Promising Pipeline Candidates
      • DE-109/ Opsiria (Sirolimus) –Santen
        • Table Figure 4: Uveitis Therapeutics Market, APAC, DE-109/Opsiria Market ($m), 2019–2023
      • CLS-TA (triamcinolone acetonide) –Clearside BioMedical
    • Heatmap for Pipeline Products
      • Table Figure 5: Uveitis Market, Comparative Efficacy and Safety Heatmap for Pipeline Products
    • Product Competitiveness Framework
      • Table Figure 6: Uveitis Therapeutics Market, Competitor Matrix for Uveitis Marketed and Pipeline Products, 2017
  • Clinical Trial Analysis
    • Failure Rate
      • Overall Failure Rate
        • Table Figure 7: Uveitis Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006–2016
      • Failure Rate by Phase and Molecule Type
        • Table Figure 8: Uveitis Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006–2016
      • Failure Rate by Phase and Molecular Target
        • Table Figure 9: Uveitis Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006–2016
    • Clinical Trial Size
      • Patient Enrollment per Product by Molecule Type and Stage of Development
        • Table Figure 10: Uveitis Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006–2016
      • Patient Enrollment per Product by Molecular Target and Stage of Development
        • Table Figure 11: Uveitis Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006–2016
      • Patient Enrollment per Trial by Molecule Type and Stage of Development
        • Table Figure 12: Uveitis Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006–2016
      • Patient Enrollment per Trial by Molecular Target and Stage of Development
        • Table Figure 13: Uveitis Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006–2016
    • Clinical Trial Duration
      • Trial Duration by Molecule Type and Stage of Development
        • Table Figure 14: Uveitis Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006–2016
      • Trial Duration by Molecular Target and Stage of Development
        • Table Figure 15: Uveitis Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006–2016
    • Summary of Clinical Trial Metrics
      • Table Figure 16: Uveitis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
      • Table Figure 17: Uveitis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
  • Multi-scenario Forecast
    • Geographical Markets
    • Asia-Pacific Market
      • Treatment Usage Patterns
        • Table Figure 18: Uveitis Therapeutics Market, APAC, Treatment Patterns (`000), 2016–2023
      • Market Size
        • Table Figure 19: Uveitis Therapeutics Market, APAC, Market Size ($m), 2016–2023
    • India
      • Treatment Usage Patterns
        • Table Figure 20: Uveitis Therapeutics Market, India, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 21: Uveitis Therapeutics Market, India, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 22: Uveitis Therapeutics Market, India, Market Size ($m), 2016–2023
    • China
      • Treatment Usage Patterns
        • Table Figure 23: Uveitis Therapeutics Market, China, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 24: Uveitis Therapeutics Market, China, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 25: Uveitis Therapeutics Market, China, Market Size ($m), 2016–2023
    • Australia
      • Treatment Usage Patterns
        • Table Figure 26: Uveitis Therapeutics Market, Australia, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 27: Uveitis Therapeutics Market, Australia, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 28: Uveitis Therapeutics Market, Australia, Market Size ($m), 2016–2023
    • South Korea
      • Treatment Usage Patterns
        • Table Figure 29: Uveitis Therapeutics Market, South Korea, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 30: Uveitis Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 31: Uveitis Therapeutics Market, South Korea, Market Size ($m), 2016–2023
    • Japan
      • Treatment Usage Patterns
        • Table Figure 32: Uveitis Therapeutics Market, Japan, Treatment Patterns (`000), 2016–2023
      • Annual Cost of Therapy
        • Table Figure 33: Uveitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2016–2023
      • Market Size
        • Table Figure 34: Uveitis Therapeutics Market, Japan, Market Size ($m), 2016–2023
  • Drivers and Barriers
    • Drivers
      • Increasing Usage of Biologics
      • Promising Late-Stage Pipeline Products Can Change Treatment Paradigm
      • Increasing Elderly Population and Incidence of Uveitis
    • Barriers
      • Uveitis – An Under-Researched Disease
      • Low Diagnosis and Treatment Rates
      • Steep Prices of Therapeutics to Slow Down Market Growth
  • Deals and Strategic Consolidations
    • Licensing Deals
      • Deals by Region and Value
      • Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
        • Table Figure 35: Uveitis Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006–2017
      • Deal Value by Stage of Development, Molecule Type, and Molecular Target
        • Table Figure 36: Uveitis Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2017
        • Table Figure 37: Uveitis Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006–2017
        • Table Figure 38: Uveitis Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006–2017
      • Key Licensing Deals
        • Table Uveitis Therapeutics Market, Global, Licensing Deals with Disclosed Deal Value, 2006–2017
    • Co-development Deals
      • Deals by region, value, year, stage of development, molecule type and molecular target
      • Key Co-development Deals
  • Appendix
    • All Pipeline Drugs by Stage of Development
      • Discovery
        • Table Uveitis Therapeutics Market, Global, All Pipeline Products, Discovery, 2017
      • Preclinical
        • Table Uveitis Therapeutics Market, Global, All Pipeline Products, Preclinical, 2017
      • IND/CTA-filed
        • Table Uveitis Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2017
      • Phase I
        • Table Uveitis, Global, All Pipeline Products, Phase I, 2017
      • Phase II
        • Table Uveitis Therapeutics Market, Global, All Pipeline Products, Phase II, 2017
      • Phase III
        • Table Uveitis Therapeutics Market, Global, All Pipeline Products, Phase III, 2017
      • Pre-registration
        • Table Uveitis Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2017
    • Market Forecasts to 2023
      • Asia-Pacific
        • Table Uveitis Therapeutics Market, Asia-Pacific, Market Forecast, 2016–2023
      • India
        • Table Uveitis Therapeutics Market, India, Market Forecast, 2016–2023
      • China
        • Table Uveitis Therapeutics Market, China, Market Forecast, 2016–2023
      • Australia
        • Table Uveitis Therapeutics Market, Australia, Market Forecast, 2016–2023
      • South Korea
        • Table Uveitis Therapeutics Market, South Korea, Market Forecast, 2016–2023
      • Japan
        • Table Uveitis Therapeutics Market, Japan, Market Forecast, 2016–2023
    • Bibliography
    • Abbreviations
    • Research Methodology
      • Secondary Research
      • Marketed Product Profiles
      • Late-Stage Pipeline Candidates
      • Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products
      • Product Competitiveness Framework
      • Pipeline Analysis
      • Forecasting Model
      • Deals Data Analysis
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report